retatrutide mechanism triple agonist glp-1 gip glucagon ly3437943 Retatrutide Beat Semaglutide by 7.9% in Phase 2 — Here's the Trial Data

retatrutide is a novel triple agonist peptide at the glucagon receptor, GIP receptor, and GLP-1 receptor. 22-24% weight loss at 48 weeks with a similar tolerability profile to #tirzepatide. @LillyPad #medtwitter #endotwitter

22.21

★★★★☆4.8 (126)

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide

22.00

★★★★★4.9 (98)

Retatrutide Guide 2023: Weight Loss, Benefits, Results, Dosage

27.04

★★★★★5.0 (157)

The power of three: Retatrutide's role in modern obesity and diabetes therapy

21.76

★★★★★4.7 (84)

Triple Agonism Based Therapies for Obesity | Current Cardiovascular Risk Reports

22.60

★★★★★4.9 (203)

Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair

26.60

★★★★★5.0 (176)

Retatrutide. The triple agonist that's redefining metabolic research. 🧬 One compound. Three receptors. Unprecedented research potential. GIP → insulin response research GLP-1 → appetite suppression studies Glucagon → energy expenditure modulation No

22.16

★★★★★4.8 (132)